Dysregulated
pre-mRNA splicing and metabolism are two hallmarks of MYC-driven
cancers. Pharmacological inhibition of both processes has been extensively investigated as potential therapeutic avenues in preclinical and clinical studies. However, how
pre-mRNA splicing and metabolism are orchestrated in response to oncogenic stress and
therapies is poorly understood. Here, we demonstrate that jumonji domain containing 6,
arginine demethylase, and
lysine hydroxylase, JMJD6, acts as a hub connecting splicing and metabolism in MYC-driven human
neuroblastoma. JMJD6 cooperates with MYC in cellular transformation of murine neural crest cells by physically interacting with
RNA binding proteins involved in
pre-mRNA splicing and protein homeostasis. Notably, JMJD6 controls the alternative splicing of two
isoforms of
glutaminase (GLS), namely kidney-type
glutaminase (KGA) and
glutaminase C (GAC), which are rate-limiting
enzymes of glutaminolysis in the central
carbon metabolism in
neuroblastoma. Further, we show that JMJD6 is correlated with the anti-
cancer activity of
indisulam, a 'molecular glue' that degrades
splicing factor RBM39, which complexes with JMJD6. The
indisulam-mediated
cancer cell killing is at least partly dependent on the
glutamine-related metabolic pathway mediated by JMJD6. Our findings reveal a
cancer-promoting metabolic program is associated with alternative
pre-mRNA splicing through JMJD6, providing a rationale to target JMJD6 as a therapeutic avenue for treating MYC-driven
cancers.